SCHEMBL29839364

SCHEMBL29839364

Cc1cccc(C23CC2CN(C(=O)c2cn(C)c4c(C)cn(C)c(=O)c24)C3)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 6/20 0.40
▸ MEN1 O00255 1/20 0.35
▸ OPRM1 P35372 1/20 0.35
▸ OPRD1 P41143 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ ALDH1A1 P00352 4/20 0.34
▸ MAPT P10636 4/20 0.34
▸ HSD17B10 Q99714 3/20 0.34
▸ NPSR1 Q6W5P4 2/20 0.34
▸ LMNA P02545 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ HPGD P15428 3/20 0.33
▸ TSHR P16473 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ HSD11B1 P28845 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ GRIN2B Q13224 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22729492 1.00 MGLL (0.40) MGLLMEN1OPRM1OPRD1KMT2A
SCHEMBL22729459 0.91 MGLL (0.41) MGLLMEN1OPRM1OPRD1KMT2A
SCHEMBL29839276 0.91 MGLL (0.39) MGLLKMT2AALDH1A1MAPTHSD17B10
SCHEMBL23116381 0.91 MGLL (0.39) MGLLKMT2AALDH1A1MAPTHSD17B10
SCHEMBL29839306 0.91 MGLL (0.41) MGLLMEN1OPRM1OPRD1KMT2A
SCHEMBL23116409 0.91 MGLL (0.39) MGLLALDH1A1MAPTHSD17B10NPSR1
SCHEMBL22729791 0.90 GRIN2B (0.39) MGLLALDH1A1ALOX15MAPK1KDM4E
SCHEMBL22729801 0.89 MGLL (0.47) MGLLALDH1A1MAPTHSD17B10NPSR1
SCHEMBL22729616 0.89 MGLL (0.44) MGLLMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL29839356 0.89 MGLL (0.44) MGLLMEN1KMT2AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11459325-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-10-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11459325-B2 Heterocyclic compound GBA1, GBA2, GALC MGLL 91/4885MEN1 1710/4885OPRM1 4680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback